|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.53 - 31.77|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||21.65|
|Dividend & Yield||1.03 (3.26%)|
|1y Target Est||N/A|
The Danish drug maker is the world’s largest manufacturer of insulin. Late yesterday, the company unveiled data from the Sustain-7 trial that shows its diabetes treatment semaglutide bested a competing treatment made by Eli Lilly (LLY) in controlling blood sugar levels and aiding in weight loss. Evercore ISI’s Umer Raffat called it a “best case outcome” for Novo Nordisk.
Announcement: Moody's: Yestar's 1 H 2017 results support its Ba3 ratings. Global Credit Research- 17 Aug 2017. Hong Kong, August 17, 2017-- Moody's Investors Service says that Yestar Healthcare Holdings ...
Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.